Portfolio

AN2 Therapeutics is a clinical-stage biopharmaceutical company focused on novel medicines targeting infectious diseases.

Appello Pharmaceuticals is a preclinical-stage company focused on advancing novel positive allosteric modulators of mGlu4 for the treatment of Parkinson’s disease.

Boragen is a small molecule development company focused on leveraging the unique chemical properties of Boron chemistry, both in crop protection and animal health.

Castle Biosciences is focused on developing and commercializing molecular diagnostics to aid health care professionals in assessing types and sub-types of tumors. Products focus on differentiating tumor types at the molecular level using various means of analyzing and comparing components of DNA.

Clearside Biomedical is an ophthalmic company specializing in the research, development and commercialization of therapeutic products delivered through a proprietary microinjection platform that targets the suprachoroidal space in the region of the eye.

Contego Medical has developed a platform based on the integration of an embolic protection filter and a treatment device into a single catheter. By offering embolic protection on the same catheter as a balloon or stent, patients are offered a safer procedure without adding time, complexity, or expense and physicians can perform the procedure in less time.

Corcept Therapeutics is a pharmaceutical company engaged in the discovery and development of drugs for the treatment of severe metabolic and psychiatric disorders.

Diabetes Care Group is a healthcare services firm focused on treating diabetes through a proprietary, proven clinical delivery model that aids patients in controlling A1c levels. It’s a Fee-for-Results model that uses subscription-based and results-based bonuses, which allow patients to take advantage of services, such as nutritional counseling, that are typically not reimbursable under most healthcare plans. Since its founding in 2009, DCG has been organizing ideas around bringing diabetes medical management together with intensive, focused diabetes education in one location.

Diagnovus is focused on developing and commercializing molecular diagnostics to aid health care professionals in assessing types and sub-types of tumors. Products focus on differentiating tumor types at the molecular level using various means of analyzing and comparing components of DNA. The Company was acquired by Aegis Sciences Corporation in January 2015.

Clinical Products sells under the Extend brand name a line of delicious, convenient snacks that are clinically proven to help stabilize blood sugar for up to 9 hours. Extend Snacks are an excellent snack choice for anyone interested in blood sugar management. The company’s bars, crisps, and shakes are available in multiple flavors and can be purchased online.

G1 Therapeutics is a clinical-stage company developing small-molecule therapies to address significant unmet needs in oncology. The company is leveraging its proprietary kinase drug discovery platform to advance a pipeline of first-in-class compounds and best-in-class drug candidates.

Ironwood Pharmaceuticals is an entrepreneurial pharmaceutical company dedicated to creating, developing, and commercializing innovative human medicines.

LineaGen provides chromosomal microarray and next generation sequencing genetic testing for individuals with autism spectrum disorder and other post-natal developmental disorders.  Lineagen also provides both pre- and post-test genetic counseling to assess the impact of the results on the patient and other family members, as well as anticipatory guidance to physicians regarding potential clinical management changes.

Mindera Corporation has developed a proprietary micro biopsy tool used to extract a patient’s transcriptome. After processing via next-generation sequencing and analysis, dermatologists will be able to make personalized diagnoses and track disease progression.

Myomo is a medical device company that has developed a custom myoelectric elbow orthotic device, enabling individuals afflicted with stroke and other neuromuscular conditions to self-initiate and control movement of a partially paralyzed arm using their own muscle signals.

NeuroTronik Limited is a medical device company focused on providing hemodynamic management of patients who are admitted with acute heart failure syndrome (“AHFS”). The NeuroTronik technology utilizes a patented intravascular electrode system capable of selectively stimulating parasympathetic and sympathetic nerves simultaneously or in a preferred cadence.

NuSirt Sciences is a biotechnology company focused on developing products targeting metabolic diseases associated with over-nutrition such as: obesity, diabetes, and inflammatory stress.

PhaseBio Pharmaceuticals is a clinical-stage biopharmaceutical company committed to developing improved biotherapeutics for the treatment of orphan diseases, with an initial focus on cardiopulmonary indications.